A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (Omicron) mRNA Vaccine (ABO1009-DP) for Sequential Immunization in the Population Aged 18 Years and Older Who Have Completed the Full Vaccination
Latest Information Update: 24 Nov 2022
At a glance
- Drugs ABO1009-DP (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Acronyms Phase 1
- Sponsors Suzhou Abogen Biosciences
Most Recent Events
- 21 Nov 2022 Planned End Date changed from 1 Aug 2023 to 25 Aug 2023.
- 19 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 26 Aug 2022 Status changed from not yet recruiting to recruiting.